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1. Introduction 
Endocrine dysfunction is common in severe sepsis and is associated with increased 
morbidity and mortality risk. Clinical detection of this heterogenous disorder is challenging, 
and the accuracy of laboratory diagnosis is complicated by the limitations in methods of 
hormonal assays and the variable definitions used in its diagnosis. This chapter will review 
the pathophysiology of neuroendocrine dysfunction during sepsis, the current evidence for 
hormone supplementation, and the use of hormonal markers and predictors of outcome 
following severe sepsis. The three hormones that have been most extensively researched 
and therefore most commonly considered for use in septic shock are corticosteroids, 
vasopressin, and insulin. We will describe the rationale, explore the controversies and 
provide recommendations for their use based on the available evidence. We present current 
recommendations for hormone therapy in adults and children, but caution that further 
research is needed to better understand the dynamic and complex endocrine responses 
during septic shock, and to develop improved methods for diagnosis and monitoring of 
patient response, so that we can determine not only which therapies to use, but how, when, 
and in which patients.  
2. Neuroendocrine dysfunction in severe sepsis 
Severe sepsis is characterized by a complex cascade involving widespread inflammation, 
enhanced coagulation, diminished fibrinolysis, immunomodulation, and release of stress 
hormones including adrenocorticotropic hormone, cortisol, vasopressin, glucagon and 
growth hormone[1]. Endocrine dysfunction plays an important role in the pathogenesis of 
multiple organ dysfunction that occurs in septic shock, and several studies have correlated 
the degree of neuroendocrine dysfunction with severity of illness[2]. Neuroendocrine 
dysfunction is common during critically illness, and can affect multiple neurohormonal 
pathways in an individual patient[3]. The hypothalamic-pituitary-adrenal (HPA) axis is a 
key coordinator of the stress response, and involves a series of complex central and 
peripheral adaptations essential for survival. The HPA axis is functionally related to the 
sympathoadrenal system, which is responsible for endogenous catecholamine secretion and 
inflammatory cytokine activation, as well as the neurohypophyseal system, which is 
responsible for vasopressin release; all pivotal integrative components in the stress response. 
The response of the anterior pituitary during severe sepsis consists of two distinct phases - 
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an acute phase, which is likely adaptive and beneficial, and a more prolonged or chronic 
phase characterized by suppression of the neuroendocrine axes resulting in hypoactivity or 
hyporesponsiveness of target hormones, which may no longer be beneficial[4]. Disruption of 
these axes, as we will discuss subsequently, compromises the adaptive response, and 
potentially survival. Differentiation between beneficial and harmful endocrine responses to 
septic shock is difficult. Nevertheless, the association between endocrine dysfunction and 
increased morbidity and mortality risk has fueled investigators to examine the role of 
hormonal therapy during sepsis. There are numerous adult studies in this area, some of 
which have revealed conflicting results. Pediatric data is much more limited. The results of 
these studies have arguably sparked more debate than provided definitive conclusions in 
the current management of sepsis.  
3. Hormonal therapies in severe sepsis 
3.1 Corticosteroids  
The normal response of the HPA axis to the stress of illness results in the release of cortisol 
from the adrenal cortex[5, 6]. This activation is crucial for the general adaptation to illness 
and the physiological response of multiple organs. The mechanism for HPA axis 
dysfunction in severe sepsis are complex and multifactorial, but can result in decreased 
production of corticotropin-releasing hormone, adrenocorticotropic hormone (ACTH), and 
cortisol, as well as dysfunction of their receptors even in the presence of “adequate” 
measured serum hormone levels. Inhibition of hormone production by cytokines and other 
peptides derived from blood cells (known as corticostatins) may compete with corticotropin 
and its receptor[7]. Septicemia itself and the medications used in its treatment may result in 
decreased corticosteroid production and increased metabolism, interfere with receptor 
signaling, as well as enzymatic and mitochondrial function that are critical in 
steroidogenesis. Furthermore, hypothalamic, pituitary or adrenal destruction by 
hemorrhage or ischemia, and the accumulation of nitric oxide, superoxide, or central 
neuropeptides can contribute to receptor down regulation of HPA hormones in patients 
with severe sepsis and septic shock[8]. The end-result of this disruption in the HPA axis is a 
syndrome of adrenal insufficiency. 
It has been suggested by the expert panels and consensus from the American College of 
Critical Care Medicine International Task Force, that the terms absolute or relative adrenal 
insufficiency be replaced by “critical illness-related corticosteroid insufficiency” (CIRCI)[5]. 
CIRCI has been defined as inadequate glucocorticoid activity in relation to the severity of 
the patient’s illness and has been most prominently investigated in cases of sepsis and septic 
shock[9-11]. It is a heterogeneous disorder that can occur as a result of dysfunction at any 
point in the HPA axis. CIRCI has been recognized in both adult and pediatric patients with 
severe sepsis, with an incidence as wide ranging from 10% up to 70% depending on the 
definition used and the study[3, 12-14]. The diagnosis of CIRCI carries with it prognostic 
implications. These patients are more likely to require vasopressor support, be refractory to 
fluid and catecholamine therapy, and are more likely to die[15]. There are several proposed 
definitions for CIRCI, but the most widely accepted definition in adults and pediatrics is an 
increment in cortisol of less than 9 µg/dL (250 nmol/L), 30-60 minutes after a 1µg ACTH 
stimulation test[5, 14]. The traditional dose of 250 µg of ACTH is a very large, 
supraphysiologic adrenal stimulus, and it is suggested that a low dose (1µg) ACTH 
stimulation is more appropriate and sensitive in distinguishing primary vs. secondary 
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adrenal failure[14, 16]. The diagnosis of CIRCI in severe sepsis is challenging for the 
following reasons: firstly, there is debate with respect to the ACTH stimulation test itself. 
While there is more evidence on the use of the 250µg stimulation test, expert panels agree 
that the 1µg stimulation test may be more physiologic, although they concede that there is a 
moderate grade of evidence supporting this recommendation[5, 17]. Secondly, confounding 
factors such as variability in sampling and cortisol assays need to be considered. 
Commercially available assays measure total cortisol, not the biologically active free fraction 
of the hormone[18]. Circulating cortisol is 90% bound to albumin and cortisol binding 
globulin, which may be decreased in severe sepsis. Hypoabuminemic septic patients may 
therefore have subnormal total cortisol levels but normal free cortisol levels[19]. Defining 
normal adrenal function can therefore be extremely challenging in the setting of severe 
sepsis and septic shock, as it needs to consider numerous variables such as the physiologic 
variation among individuals, the performance of commercially available cortisol assays, 
levels of free versus bound cortisol, and medications that may interfere with cortisol 
secretion or regulation. 
3.1.1 The evidence for corticosteroid supplementation in severe sepsis 
Corticosteroids have been studied extensively as an adjunctive therapy in septic patients for 
over 40 years and has been a subject of controversy for decades. As corticosteroid 
insufficiency can occur in severe sepsis, the rationale for steroid use in this setting is to 
attenuate the exaggerated systemic inflammatory response and cytokine activation, improve 
hemodynamic function, and reverse the HPA axis suppression and subsequent adrenal 
insufficiency. Corticosteroids have been shown to improve the vascular response to 
exogenous catecholamines in the septic state through its up-regulation of adrenergic 
receptors, and inhibition of vasodilatory stimulants such as nitric oxide synthase, 
prostaglandin E1 and prostacyclin[20]. Corticosteroids may also reverse vascular 
hyporesponsiveness to vasopressin[21]. 
Clinical trials of corticosteroids date back as far as 1963, and although it may now be 
recognized that CIRCI is common in septic shock, consensus on how best to treat this 
phenomenon is yet to be reached. This stems from several challenges – the difficulties in 
establishing its diagnosis as described above, the controversies on appropriate dosing of 
corticosteroids and contradictory results from numerous trials on the efficacy of steroid 
replacement in this setting, and finally, the identification of CIRCI is not predictive of a 
favourable response to corticosteroids. Nevertheless, meta-analyses, reviews and guidelines 
have advocated the use of low-dose hydrocortisone in patients with septic shock[9-11, 22]. 
Arguments in favor of steroid replacement are that CIRCI is common in this population, 
steroids may results in a more rapid shock reversal and therefore improve survival, and 
steroids may be have additional advantages when septic shock is complicated by acute 
respiratory distress syndrome. Arguments against its use include the increased risk of 
adverse effects such as superinfection, critical illness myopathy, hyperglycemia and 
ultimately increased mortality[11, 23]. Hence, there are multiple questions with respect to 
CIRCI that pertain not only to should we treat, but who to treat and how to treat. 
The earlier sepsis trials of the 1980’s evaluated high-dose corticosteroids and found no 
mortality reduction, but a trend towards harm[24]. Further analyses suggested an inverse 
relationship with steroid dose and survival - the higher the dose the lower the survival rate. 
Subsequent trials performed in the 1990’s in which lower, more physiologic doses of 
glucocorticoids were administered for longer courses demonstrated improved shock 
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reversal, but a more heterogenous beneficial effect on mortality[22]. The largest of these 
trials, conducted by Annane et al. demonstrated improved survival with 7 days of 200 mg 
hydrocortisone and 50 mg fludrocortisone per day when compared to placebo, in patients 
with evidence of CIRCI (ACTH nonresponders)[25]. There was no significant difference in 
mortality between groups amongst responders. A criticism of this trial is that 72 of 229 
nonresponders received etomidate, an inhibitor of 11 β-hydroxylase and hence cortisol 
production[26]. 94% of the etomidate treated patients in the Annane trial demonstrated 
CIRCI. This limitation in generalizability of this study coupled with concerns regarding side 
effects tempered the initial enthusiasm for steroid use in septic shock. Meta-analyses 
published in 2004 demonstrated improved shock reversal with steroids at lower doses, dose 
related adverse effects, but no impact on overall mortality[11, 22].  
There have been at least seven prospective randomized controlled trials published since 
2004. The largest of these, the multi-center CORTICUS trial, anticipated enrolling 800 
patients but recruitment was stopped at 499 patients because of slow enrolment and other 
logistical reasons[27]. Twenty-eight day mortality was similar between the hydrocortisone 
(34%) and the placebo groups (31%), however mortality was insignificantly higher in non-
responders. Interestingly, steroid treatment accelerated shock reversal more so in 
responders, but was associated with an increased incidence of nosocomial infection, 
superinfection, and hyperglycemia. The investigators concluded that routine hydrocortisone 
should not be routinely used in adults with septic shock, and the ACTH stimulation test 
does not identify patients who might benefit from hydrocortisone therapy[28]. The 
discrepant findings of the CORTICUS and the Annane trial have sparked debate as to why 
their findings differ. Possible contributing factors are that CORTICUS enrolled patients later 
(up to 72 hours in septic shock), with lower disease severity, as opposed to targeting 
patients early in their disease (3-8 h) who are poorly responsive to vasopressors, which was 
the Annane protocol. An updated meta-analysis combining all trials published after 1997 
concluded that low-dose corticosteroids consistently improves shock reversal, but decreases 
mortality only patients with more severe septic shock who are at the highest risk of 
death[29]. Low-dose steroids appear to increase mortality or have no effect in less severely 
ill patients with sepsis. 
In contrast to the adult literature, there are very few clinical trials of corticosteroid use in 
pediatric septic shock, the majority of which have been conducted in the setting of Dengue 
shock, and have lead to conflicting conclusions. Min et al in a double-blinded randomized 
controlled trial (RCT) reported a lower case fatality rate following 3 days of adjunctive 
hydrocortisone (19%), compared to placebo (44%, p=0.005)[30]. However in a subsequent trial 
by Sumarmo et al, while underpowered (n=97), found no benefit following a single dose 50 
mg/kg of hydrocortisone within 6 hours of randomization[31]. A Cochrane systematic review 
evaluated 4 trials that enrolled a total of 284 subjects, and concluded that there was no benefit 
from adjunctive corticosteroid therapy in children with Dengue shock[32]. The have been two 
RCTs in the preterm population both of which demonstrated a short term beneficial 
hemodynamic effect of steroids in the setting of refractory hypotension of unspecified etiology, 
however no differences in clinical outcomes have been demonstrated.[33, 34] A large 
retrospective cohort study utilizing the Pediatric Health Information System administrative 
database (n=6693) suggested that adjunctive corticosteroid therapy for pediatric severe sepsis 
was associated with a variety of worse outcomes (mortality rate of 30% in children who 
received steroids compared to 18% in those who did not), however the study was criticized for 
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its lack of severity of illness data in the study population.[35] A post-hoc analysis of the 
RESOLVE (REsearching severe Sepsis and Organ dysfunction in children: a gLobal perspective 
F1K-MC-EVBP) trial of activated protein C for pediatric severe sepsis, which is the largest 
prospective pediatric sepsis clinical trial to date, found no difference in outcomes (mortality, 
days requiring vasoactive infusion or mechanical ventilation, organ failure resolution) 
amongst those who received corticosteroids and those who did not[36]. The evidence in 
pediatrics is far from conclusive, and further prospective, RCT data evaluating corticosteroids 
use specifically in pediatric and neonatal septic shock is very much needed. 
3.1.2 Recommendations for corticosteroid use in sepsis 
The effects of corticosteroids in sepsis are dependent on both the dose used and severity of 
illness. High-dose steroids during sepsis are harmful, while low-dose steroids improves shock 
reversal, and may have a mortality benefit in the sickest patients with refractory septic shock. 
Until further definitive data are available on the population most likely to benefit from 
therapy, the decision to administer low-dose steroids during sepsis should be individualized, 
and considered in relation to the patient’s severity of illness, and risk factors from their 
endocrine or corticosteroid history. ACTH stimulation test is not routinely recommended for 
the purposes of identifying patients who may benefit from steroid therapy. Having considered 
the controversies and nuances of the current evidence, the 2008 Surviving Sepsis Campaign 
International Guidelines made the following recommendations, using the Grades of 
Recommendation Assessment, Development and Evaluation (GRADE) criteria to indicate the 
strength of the evidence and recommendations[10]: the use of low dose steroids (e.g. < 300 
mg/day of hydrocortisone) should be considered for in septic adults (and children) who 
remain hypotensive despite adequate fluid and vasopressors (Grade 2C); the current ACTH 
simulation test that assesses total serum cortisol is not recommended to identify the subset of 
adults with septic shock who might benefit from hydrocortisone (Grade 2B); hydrocortisone is 
preferred over dexamethasone (Grade 2B); oral fludrocortisone for added mineralocorticoid 
activity may be considered (Grade 2C); corticosteroid therapy may be weaned once vasoactive 
support is no longer required (Grade 2D); and the use of corticosteroid supplementation 
should not be used to treat sepsis in subjects whose shock reverses after fluid and pressors, or 
in the absence of septic shock unless indicated by the patient’s endocrine history(Grade 1D). 
Despite the lack of evidence supporting the use of short-term steroid therapy in pediatric 
patients with septic shock, it appears that approximately 50% of pediatric intensivist would 
empirically treat their septic patients with steroids[13]. Until further data is available, given 
that CIRCI in pediatric septic shock is associated with a poor prognosis, the guidelines 
recommend that stress dose steroids (hydrocortisone 50 mg/m2/day) be considered in 
children with fluid and catecholamine resistant septic shock who have suspected or proven 
risk factors for corticosteroid insufficiency (purpura fulminans, chronic steroid therapy, 
pituitary or adrenal abnormalities). These drugs should be weaned off as soon as the 
hemodynamic status of the patients allows, particularly when vasopressors are no longer 
required. Potential inhibitors of cortisol secretion such as etomidate or ketoconazole should be 
avoided in patients with sepsis. 
3.2 Insulin 
Hyperglycemia is common during severe sepsis and septic shock, due to the presence of 
circulating counter-regulatory hormones, medications such as catecholamines and 
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glucocorticoids, and the activation of metabolic pathways such as hepatic glycogenolysis 
and gluconeogenesis, decreased hepatic glucose utilization, impaired insulin mediated 
glucose uptake, and cytokine related insulin resistance[37]. The prevalence of 
hyperglycemia in critically ill patients can be as high as 50% to 75%, depending on the 
definition used[38]. Historically, moderate hyperglycemia was considered at best to be an 
adaptive response to critical illness, and at worst, a marker of severity of disease. However, 
several studies have clearly demonstrated an association between hyperglycemia and 
mortality in both adult and pediatric non-diabetic critically ill patients[39]. Hyperglycemia 
has also been associated with an increased risk of sepsis, critical illness polyneuropathy, 
duration of mechanical ventilation, length of hospital stay[40]. Proposed mechanisms by 
which hyperglycemia increases morbidity and mortality include pro-inflammatory effects 
by stimulating reactive oxygen species and interleukin-8, prothrombotic effects, impaired 
innate immunity, and increased oxidative stress. Reversal of hyperglycemia and its sequelae 
with insulin therapy therefore has scientific rationale. Insulin in itself may have additional 
beneficial effects including partial correction of dyslipidemia, prevention of excessive 
inflammation, and attenuation of the cortisol response to critical illness[41]. 
3.2.1 The evidence for insulin therapy  
The landmark RCT by Van den Berge et al. provided the first clinical evidence that 
maintaining strict glycemic control with intensive insulin therapy (IIT) in an adult postsurgical 
intensive care unit (ICU) (target glucose range 80 to 110 mg/dL) provided a mortality, and in 
some instances, a morbidity benefit, with the greatest mortality reduction of the subgroup of 
patients with an ICU stay of > 5 days[42]. The IIT group also experienced reductions in 
duration of mechanical ventilation, ICU stay and critical illness-associated polyneuropathy. 
This study was criticized for its lack of generalizability as it was conducted in a single center, 
and participants were mainly cardiothoracic surgical patients, many of whom were receiving 
total parenteral nutrition. In a subsequent study conducted in adult medical ICU patients by 
Van den Berghe, IIT did not reduce mortality, but resulted in reductions in length of ICU and 
hospital stay, duration of mechanical ventilation, and incidence of new renal injury, 
particularly in the group of patients with an ICU stay of 3 or more days[43]. In fact, mortality 
was actually greater among those receiving IIT with ICU stay less than 3 days. Since the 
original Van den Berghe trials, IIT has not been shown to improve outcomes in subsequent 
multicenter studies involving patients with severe sepsis or in a general ICU population[44, 
45]. Two large multi-center trials (VISEP and GLUCONTROL) were both stopped early for 
safety reasons because of adverse events related to hypoglycemia in the IIT arm, and no 
mortality difference[44, 46]. In the VISEP study, IIT increased the rate of severe hypoglycemia 
(17.0% vs. 4.1%) and serious adverse events (10.9% vs. 5.2%, p = 0.01) in critically ill adults with 
sepsis[44]. In the GLUCONTROL trial, treating to achieve a moderately hyperglycemic goal 
(140-180 mg/dL) yielded similar survival, length of stay with fewer hypoglycemic reactions 
compared with IIT[46]. The authors of both studies concluded that tight glycemic control with 
IIT offered no apparent benefits, but increased the risk of hypoglycemia.   
The Normoglycemia in Intensive Care Evaluation – Survival Using Glucose Algorithm 
Regulation (NICE-SUGAR), and international multicenter trial involving 6104 patients, is 
the largest trial of intensive insulin therapy to date[45]. This trial compared conventional 
glucose control (≤ 10.0 mmol/L or 180 mg/dL) to intensive glucose control (4.5 to 6.0 
mmol/L or 81 to 108 mg/dL) in critically ill patients, and concluded that using insulin to 
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achieve a conventional glucose control resulted in lower 90 day all cause mortality. 
However, the subgroup analysis did not reveal a significant difference in treatment effect in 
the subgroup of patients with severe sepsis (21% of patients). Subsequent meta-analyses 
incorporating the results of all trials of this nature reveal that IIT significantly increases the 
risk of hypoglycemia while conferring no overall mortality among critically ill patients, 
compared to conventional insulin therapy. However, there may be benefits of IIT in the 
subset of patients treated in surgical ICU’s[47, 48]. As corticosteroid therapy induces 
potentially detrimental hyperglycemia in septic shock, the benefit of intensive insulin 
therapy in patients treated with hydrocortisone was evaluated (COIITSS Study), but did not 
improve mortality in patients with septic shock when compared to conventional insulin 
therapy[49]. 
As expected, the data in pediatrics is limited. While a relationship between hyperglycemia 
and poor outcomes have also been identified in this population, hypoglycemia in the 
absence of insulin therapy, and increased glucose variability in particular appear to have an 
even stronger association with mortality and length of stay[38, 50]. To date, there is only one 
prospective randomized controlled trial to date by Vlasselaers et al, published in 2009.[98] 
This trial randomized 700 critically ill children (317 infants aged 1 year,  and 383 children 
aged ≥ 1 year) to an age-adjusted intensive insulin group (i.e. target glucose range of 2.8-4.4 
mmol/L in infants, and 3.9-5.6 mmol/L in children), or  a conventional group where insulin 
was initiated only when blood glucose exceeded 11.9 mmol/L. The investigators found that 
intensive insulin therapy in this trial of predominantly cardiac surgical patients, resulted in 
a significant decrease in PICU stay, reduced mortality and an attenuated inflammatory 
response on day 5, as indicated by lower C-reactive protein values. The risk of secondary 
infections was also significantly lower in the intensive insulin group. The risk of 
hypoglycemia however, was significantly higher in the intensive insulin group. They also 
observed that patients who developed hypoglycemia had a higher risk of death than those 
who were not hypoglycemic, although this difference was not statistically significant. It has 
been suggested that glucose reperfusion after hypoglycemia may trigger neuronal death, 
rather than hypoglycemia itself.[99] As the excess neurological deaths in this trial occurred 
in the conventional and not the intensive insulin arm, the authors conclude that the short-
term benefits of preventing hyperglycemia in critically ill children may outweigh those of 
hypoglycemia, provided that hypoglycemia is recognized and treated promptly. 
3.2.2 Limitations of insulin therapy in sepsis  
The limitations of insulin therapy for glucose control in critically ill patients with sepsis are 
primarily three-fold. Firstly, blood glucose variability, especially in children, may be a more 
important marker of poor outcome than isolated blood glucose levels per se[51]. Secondly, 
blood glucose monitoring in critically ill patients is notoriously inaccurate by nature of 
intermittent testing as opposed to real-time results, and the variable methods of 
measurement and levels of quality control[52]. Furthermore, symptomatic monitoring is also 
hindered as counter-regulatory responses in critically ill septic patients are often impaired, 
and ICU therapies like sedation may mask symptoms of severe hypoglycemia. The third 
and most obvious limitation is the risk of hypoglycemia, which has been clearly identified in 
the multiple large adult RCTs, as well as the pediatric observational studies. In fact, the rate 
of hypoglycemia is highest in children with sepsis (28.6%), in the absence of insulin 
therapy[50]. While there may be subgroups of adult patients who may benefit from IIT[48], 
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there is clear evidence that children are more susceptible to developing hypoglycemia, and 
the risks of mortality, morbidity, and irreversible neurological sequelae of hypoglycemia in 
the developing brain is greater[38]. 
3.2.3 Recommendations for insulin and glycemic control in sepsis 
Although current guidelines from the American Diabetes Association, the American 
Association of Clinical Endocrinologists and other organizations such as the Surviving 
Sepsis Campaign currently recommend tight glycemic control with insulin therapy, more 
recent meta-analyses of the largest trials to date suggest that these recommendations should 
be revised for septic patients who are critically ill[48]. Less restrictive target glucose values 
in the range of 140-180 mg/dL appear safer than 80-100 mg/dL in critically ill adults, 
although it is unclear whether there may be specific subgroups of adult patients who may 
benefit from IIT and be at lower risk of hypoglycemic events. We recommend that 
hypoglycemic and variable glucose episodes should be avoided in all patients with sepsis. 
The risk-benefit ratio for insulin therapy in critically ill children with sepsis remains unclear. 
While there is a suggestion from the pediatric literature that glycemic control may be 
beneficial in reducing morbidity and mortality, the optimum blood glucose targets in 
children remain uncertain. Until further prospective data is available specifically in this 
population, it is reasonable to target blood a glucose control of ≤ 10 mmol/L as defined by 
the definitive adult trial. However, further research on this subject in critically ill children is 
needed, and the long-term sequelae of both hypo- and hyperglycemia in this population 
should be further investigated. Well-developed, detailed and user-friendly protocols and 
extensive education of caregivers are essential to any insulin therapy and glucose 
monitoring protocol. Until a more accurate and reliable continuous blood sensor is 
available, the most reliable method of blood glucose measurement (i.e. arterial point-of-care) 
is recommended, particularly in the patient at risk, and capillary blood samples should be 
interpreted with caution. 
3.3 Vasopressin 
Vasopressin is a neurohypophyseal peptide hormone that is an attractive adjunctive agent 
in vasodilatory septic shock for the following reasons: 
1. Vasopressin inactivates the key mechanisms responsible for the pathogenesis of 
vasodilatation and catecholamine resistance[53].  
2. Although it is a potent systemic vasoconstrictor, vasopressin demonstrates organ 
specific vasodilator effects in the pulmonary, cerebral and coronary circulations, 
potentially preserving vital organ perfusion. It also has been shown to increase urine 
output and creatinine clearance in patients with septic shock, when compared to 
norepinephrine[54].   
3. Vasopressin influences multiple other hormone responses including ACTH, and 
consequently cortisol release, important considerations in the setting of HPA axis 
dysfunction during septic shock[54, 55]. Vasopressin also stimulates prolactin secretion, 
an important mediator of cellular immune response during sepsis[56]. 
4. Vasopressin insufficiency, either absolute - as a result of depletion or impaired release 
from neurohypophyseal stores; or functional - as a result of cytokine mediated receptor 
down regulation, has been demonstrated in both adults and perhaps children with 
septic shock[57]. 
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3.3.1 Assessing the vasopressin axis 
There is a surge in endogenous vasopressin levels during sepsis, however inappropriately 
low levels to the order of 3-10 pg/mL have been identified in septic shock. The detection of 
endogenous deficiency by measuring circulating vasopressin levels is limited by the fact that 
the mature hormone is unstable, has a short half-life, and circulates largely attached to 
platelets. Copeptin, a stable vasopressin precursor, has recently been identified as a stable 
and sensitive surrogate marker for vasopressin release, and has been proposed as a more 
sensitive and potential prognostic biomarker in sepsis[58]. Others have suggested that the 
ratio of vasopressin to norepinephrine levels should be considered a reflection of adequacy 
of vasopressin homeostasis relative to adrenocorticoid homeostasis. The vasopressin/ 
norepinephrine ratios in sepsis and severe sepsis are similar (1/175) while they are much 
lower when shock ensues (1/1000)[21]. 
3.3.2 The evidence for vasopressin supplementation in severe sepsis  
Numerous adult trials suggest short term benefits of vasopressin, the Vasopressin and Septic 
Shock Trial (VASST) conducted by Russell et al. evaluated the effect of low dose arginine 
vasopressin (0.01-0.03 U/min) as an adjunctive agent compared to norepinephrine alone, on 
mortality in 779 adult patients in septic shock[59]. There was no difference in 28-day mortality 
between groups (35.4% vs. 39.3%, p = 0.26). Although the authors had predicted that based on 
its vasoconstrictor potency, vasopressin would be more efficacious in the stratum of patients 
with more severe septic shock (baseline requirement of ≥ 15 µg/kg/min norepinephrine), they 
observed a significant reduction in mortality in the subgroup of patients with less severe septic 
shock (baseline of 5-14 µg/kg/min norepinephrine). While the authors conclude that these 
subgroup findings should be hypothesis generating only, it has sparked further debate as to 
whether higher doses of vasopressin should be used in patients with more severe shock, and 
should be thus evaluated in future studies. A post hoc analysis of the VASST trial suggested 
that combined vasopressin and corticosteroid therapy was associated with decreased mortality 
and organ dysfunction than norepinephrine and corticosteroids[60]. A subsequent open-label 
trial by Torgersen and colleagues demonstrated that higher doses of vasopressin (0.067 
IU/min) resulted in improved hemodynamic control without increased adverse effects, 
compared to lower doses of 0.033 IU/min in patients with vasodilatory septic shock[61]. 
There are at present at least 18 published observational studies reporting on a collective total 
of only 145 children, that arginine vasopressin and its longer lasting synthetic analogue, 
terlipressin increase systemic blood pressure, decreases inotrope or vasopressor 
requirement, and increases urine output in children with catecholamine-resistant shock[57, 
62]. The doses used in these studies varied substantively, ranging from 0.00002 U/kg/min 
to 0.002 U/kg/min of vasopressin, and terlipressin dosing administered anywhere from 
every four hourly, to continuous infusion. The Vasopressin in Pediatric Vasodilatory Shock 
trial which evaluated the safety and efficacy of low dose vasopressin as an adjunctive agent 
found no difference in the time to hemodynamic stability, organ free failure days or 
magnitude of vasoactive agent use between the vasopressin and placebo groups[63]. While 
there was no statistical difference in the adverse event rates, there was a trend towards 
increased mortality in the vasopressin group. 
3.3.3 Adverse effects of exogenous vasopressin 
Because of its potent vasoconstrictor action, potential adverse effects of low dose 
vasopressin include increase in myocardial after-load, reductions in oxygen delivery, 
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impaired tissues perfusion and ischemic tissue injury. Thrombocytopenia and increases in 
aminotransferases activity and bilirubin concentrations have also been reported. These 
adverse effects appear to be dose-dependent, and more commonly noted with doses of 
greater than 0.04 U/min of vasopressin or 2 µg/kg/h of terlipressin[21]. However, some of 
the data is conflicting, and it is yet unclear whether the hemodynamic alterations represent 
adaptive response to stabilized blood pressure, or the impaired tissue perfusion is an 
epiphenomenon of the severity of underlying disease rather than a specific side effect of 
vasopressin or concurrent catecholamine pressor administration.[64] Both the VASST and 
Vasopressin in Pediatric Vasodilatory Shock trials reported no significant difference in 
adverse event rates between the vasopressin and control groups[59, 63]. 
3.3.4 Recommendations for vasopressin use in sepsis 
There are currently no recommendations for routine testing for endogenous vasopressin 
levels in the setting of sepsis.  Catecholamine infusions remain the first line vasopressor 
agents of choice in adults with septic shock[10]. Based on the results of VASST, low dose 
vasopressin infusion may be considered as an adjunctive agent, however, with the 
anticipation of an effect equivalent to that of norepinephrine alone. Higher doses of 
vasopressin may have short-term beneficial hemodynamic effects in septic shock refractory 
to traditional vasopressor therapy, however its effect on clinically important patient 
outcomes is unknown. As with any vasopressor therapy, close monitoring of end-organ 
perfusion, awareness of potential side effects, and measurement of tissue flow where 
possible are essential. Pediatric recommendations are based on limited evidence and one 
should be aware that children more commonly present with low cardiac output, high 
systemic vascular resistance during septic shock, and commonly evolve from one 
hemodynamic state to another[65]. Vasoactive therapy should therefore be tailored 
according to the patient’s clinical status. There is no evidence that adjunctive vasopressin 
therapy is beneficial in pediatric sepsis at the present time. 
4. Hormonal markers and predictors of outcome in sepsis 
The clinical diagnosis of sepsis is made in the presence of a systemic inflammatory response 
syndrome (SIRS) and a proven or suspected source of sepsis. Our ability to accurately and 
promptly diagnose sepsis is limited due to the lack of a definitive test in this setting. Positive 
cultures may account for only 10% of all blood culture results reported, of which up to 50% 
may be due to contamination. This in turn has significant potential financial and healthcare 
costs to the patient and the healthcare system[66, 67]. Despite the expanding research on 
treatment modalities in this field, the mortality rate in sepsis remains unacceptably high, 
often due to delayed diagnosis and treatment. According to United States data, the 
incidence of sepsis and number of sepsis-related deaths continue to rise, although there is a 
slight decrease in the age-adjusted mortality rate among patients with sepsis in recent 
years[68]. In view of this diagnostic and therapeutic dilemma, the search of an unequivocal 
and rapid confirmatory test to distinguish septic from non-septic causes of SIRS is 
paramount. There have been enormous attempts to identify prognostic markers of early 
sepsis and accurate risk prediction that may better direct therapy and diagnosis and thus 
improve mortality and morbidity in septic patients. In this context, several endocrine 
markers and mediators of sepsis have been investigated as potential early indicators and 
potential predictors of outcome in sepsis. Many of these hormonal assays are still under 
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investigation and are not commercially available. We discuss some of the current research 
on hormonal markers of sepsis in the remaining section of this chapter. 
4.1 Procalcitonin 
Procalcitonin is a 116 amino acid peptide with a sequence identical to that of prohormone 
calcitonin but devoid of hormonal activity. During sepsis, circulating levels of procalcitonin, 
increase several-fold to several thousand-fold. Procalcitonin is released into the circulation 
within 3 hours of endotoxin injection, plateaus at 6 hours, and remains elevated for 24 
hours, making it an attractive and sensitive hormonal marker of early sepsis[69]. 
Procalcitonin measurement was first described by Assicot et al to differentiate between 
bacterial and non-bacterial causes of sepsis, and while it is now increasingly used as an early 
marker of bacterial infection, procalcitonin can be increased in noninfectious conditions, and 
remain low in certain bacterial infections, such as bacterial pulmonary aspiration[70-72]. 
Procalcitonin appears to offer better specificity over other biomarkers such as C-Reactive 
Protein, in differentiating between viral and bacterial causes of fever, and in distinguishing 
invasive from noninvasive infections[73, 74]. More recently, procalcitonin has been 
advocated as a clinical tool to guide antimicrobial therapy in patients with suspected 
infections. Several randomized controlled trials have reported a significant reduction in 
antibiotic exposure and duration based on serial procalcitonin measurements, compared to a 
standard approach[75-77]. An association between decreasing levels of procalcitonin and 
favourable outcomes has been suggested by several investigators, however further 
validation studies are required before any firm conclusions can be made[72, 78]. 
4.2 Thyroid 
Thyroid hormones play an important role in the adaptation of metabolic function to stress 
and critical illness. Thyroid function abnormalities are often observed during critical illness 
but are transient and may not represent underlying thyroid disease. There is evidence that 
lower baseline thyroid hormone values, including triiodothyronine (T3), thyroxine (T4), and 
thyroid stimulating hormone (TSH) can be substantially lower in septic compared to non-
septic patients of similar critical illness severity, and that these abnormalities are associated 
with a worse outcome in patients with sepsis or septic shock[79]. Low T3 can be attributed to 
increased de-iodination of T4 to reverse T3 (rT3), rather than T3, and increased catabolism of 
T3 to 3,3-diiodothyronine. Low total and free T4 and low TSH levels can be observed in 
severe sepsis and septic shock due to decrease in plasma T4-binding globulin or 
transthyretin as well as accumulation of substances that lower the plasma thyroid hormone-
binding capacity[80]. However, the pattern of abnormal thyroid profiles are not consistently 
observed between studies, with more pediatric studies reporting thyroid function 
abnormalities. Reasons for discordant findings may be attributed to age related hormonal 
differences - plasma thyroid hormone levels are higher than older children and adults in the 
first few months of life, due to the TSH surge that occurs in the immediate postnatal period, 
and elevated TBG levels secondary to maternal estrogen. Other reasons for variable findings 
may be attributed to differences in the hemodynamic response to septic shock in children, 
and thus the type of vasoactive support; dopamine can suppress the pituitary release of TSH 
and thus potentially the production of T3, while norepinephrine is believed to stimulate the 
secretion of TSH. It is however, generally accepted that alterations in thyroid hormone 
observed during septic shock constitute part of an adaptive metabolic response, and that the 
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majority of patients recover normal thyroid function once their critical illness subsides[81]. 
Nevertheless, thyroid disorders are relatively common in the general population, with an 
estimated prevalence of 1% to 10%, and hence a subset of patients with septic shock can 
have true underlying hypothyroidism. High TSH or reduced rT3 may be suggestive of such 
a diagnosis. 
The hypothesis of relative thyroid insufficiency and its association with a worse outcome 
has led to several studies on thyroid supplementation during sepsis. However, despite early 
animal studies showing beneficial effects of thyroid supplementation particularly on lung 
mechanics and vasoactive requirements during sepsis[82], human studies have failed to 
demonstrate a beneficial effect from thyroid hormone replacement in this setting[79]. 
Thyroid hormone supplementation during sepsis can lead to a reciprocal decrease in TSH, 
which in turn can adversely effect the adaptive immune response. 
In summary, thyroid hormone abnormalities are very common in septic patients and hence 
future studies are required to establish the strength of this association, or if a causal 
relationship exists between thyroid hypofunction and adverse outcome. The role of thyroid 
hormone abnormalities as an adjunctive predictor of outcome warrants further evaluation 
Follow-up thyroid function tests are recommended if abnormal levels are measured during 
severe sepsis, as the majority of these abnormalities are transient. 
4.3 Growth hormone 
Activation of the HPA axis in critical illness results in an alteration in pulsatile release of 
growth hormone (GH) from the somatotropes. Down regulation of insulin-like growth 
factor 1 (IGF1) and GH binding proteins result in an acquired peripheral GH resistance 
during severe sepsis which in turn promotes protein catabolism and negative nitrogen 
balance[83]. There is evidence that GH resistance and the resultant increase in circulating 
GH concentrations have deleterious effects in critically ill patients. Increased GH levels has 
been shown to correlate with poor outcome in children with menincococcal sepsis and septic 
shock[84]. Increased GH has also been found to correlate with severity of disease and 
appears to be an independent predictor for mortality in critically ill adults but does not 
discriminate between septic and non-septic patients[85]. It is also unclear how GH is 
influenced by difference metabolic factors such as glucose control, insulin administration, 
and nutrition. Unfortunately, trials with recombinant GH targeted at overcoming the GH 
resistance induced catabolism have not been promising but in fact have demonstrated 
potential harm due to emergence of uncontrolled infections and the development of 
multiple organ failure[86]. At this point in time, the potential benefits of GH measurements 
in sepsis remain unclear and is therefor not recommended. 
4.4 Copeptin 
As discussed earlier, measuring circulating vasopressin levels is challenging as the mature 
hormone is unstable, has a short half-life and is largely attached to platelets. Copeptin, a 
stable peptide of the vasopressin precursor, is secreted in an equimolar ratio and thus 
mirrors the production of vasopressin[87]. Copeptin measurements have been shown to be 
much more stable and easy to determine than vasopressin, and has therefor been proposed 
as a sensitive and potential prognostic marker in patients with sepsis. Copeptin levels do 
appear to be increasingly elevated according to severity of illness from patients with sepsis, 
to severe sepsis and septic shock, however the optimal cut-off level has a sensitivity of 61.5% 
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and a specificity of 83.8%[88]. Copeptin is not specific to sepsis, and increased levels are also 
a marker of heart disease and ischemic stroke. Furthermore, copeptin levels may be affected 
by exogenous corticosteroid therapy, and in renal insufficiency[88]. 
4.5 Leptin 
Leptin is an adipose-derived hormone known for its contribution to energy metabolism and 
satiety signaling in the hypothalamus. Elevated baseline levels of leptin are found in obese 
patients, and obesity appears to be an independent, “dose-dependent” risk factor for sepsis 
morbidity and mortality[89]. There is evidence that leptin is also involved in cell-mediated 
immunity and cytokine crosstalk. Human septic patients have evidence of increased 
circulating leptin concentrations which correlate with severity of illness, and hence it has 
been postulated that leptin may play a critical role in the pathogenesis of sepsis-associated 
multi-organ dysfunction[90]. It has also been suggested that elevated leptin levels may aid 
in distinguishing between sepsis and non-infectious SIRS[91]. However, research in this area 
is in its infancy, and further studies are required to determine the pathogenic mechanisms of 
leptin, and the diagnostic and therapeutic potential of leptin family molecules in human 
sepsis. 
4.6 Age and sex hormone related phenomena during sepsis  
Differences in hormonal profiles have been suggested as the cause of gender-based 
differences in the incidence and outcomes from severe sepsis. The incidence of sepsis 
appears to be 15% to 28% higher in males than in females in both the pediatric and adult 
populations[68, 92]. Among septic patients, even microbes may have a predilection for 
certain sexes. In a large cohort study of septic patients admitted to US hospitals, men were 
more likely than women to be infected with Gram-positive organisms after controlling for 
source of infection[93]. Whether gender related differences in sepsis translates into a higher 
mortality risk remains unclear[68, 94]. Sex hormones or sex-related gene polymorphisms 
may protect women against sepsis and death from sepsis. Estrogens and prolactin may 
confer some protection in women however there are additional non-hormonal based factors 
such as a differential immune response, sociocultural, racial background, economic or 
personal health-related behaviours between men and women, that account for the gender-
related differences in incidence and outcomes from sepsis[94]. 
Neuroendocrine dysfunction appears to differ significantly between children and adults and 
hence it is suggested that age related differences may contribute to variations in disease 
course, physiologic response and clinical outcomes in these populations[95]. Mortality from 
pediatric septic shock is significantly lower than in adults[96]. The hemodynamic profile 
during severe sepsis in children more commonly presents as cardiogenic dysfunction as 
opposed to the vascular failure seen in adults[97]. As a result, children with fluid-refractory 
septic shock are frequently hypodynamic and respond to inotrope and vasodilator therapy, 
while vasopressor therapy is recommended as the first line agent in adult patients[10, 97]. 
These differences in physiologic response therefore call for a diagnostic and therapeutic 
approach that is tailored dependent on the patient’s age. 
5. Conclusion 
Severe sepsis and septic shock remains one of the most challenging problems in medicine 
today, and in our search for potential therapies to reverse end-organ sequelae of infection, 
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we are eager to embrace the concept of endocrine support to supplement the antimicrobial 
and cardiorespiratory support during the management of the sickest of these patients. 
While hormonal therapy may play an important role in the management of severe sepsis 
for hormone therapy in sepsis, we have yet to fully understand the dynamic 
compensatory mechanisms, signaling pathways and complex interdependence of multiple 
hormonal responses, such that replacement therapy with exogenous hormone with the 
rationale of restoring normal or “physiologic” values, or to reverse target organ receptor 
resistance, may be too simplistic a therapeutic approach. We have yet to fully understand 
the precise mechanisms by which these hormones participate in sepsis and non-infectious 
SIRS, and the complex role each may play in modulating the inflammatory and immune 
responses during severe infection, and whether these responses are adaptive or 
maladaptive. Limitations in predicting who may respond and potentially benefit from 
such therapies, together with how to define or diagnose dysfunction within a hormonal 
axis, add further challenges. There are many stress hormones that mirror the severity of 
illness during sepsis, however with the possible exception of procalcitonin, none are 
specific enough to consistently discriminate between infectious and non-infectious causes 
of SIRS such that one can currently be recommended for routine use as an early diagnostic 
and independent prognostic marker. Nevertheless based on emerging research, it is likely 
that hormonal assays may become adjunctive to the predictive capacity of validated 
prognostic scoring tools in the future. There is evidence that corticosteroid and insulin 
therapy in specific subgroups of critically ill septic patients can be beneficial. The many 
controversies and ongoing debates ensure that this area of research will continue to 
evolve, which will hopefully enhance our ability to not only detect hormone dysfunction, 
but also predict outcome, and ultimately refine our diagnostic, therapeutic and prognostic 
approaches in septic patients. 
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